Director/PDMR Shareholding

RNS Number : 6133J
GlaxoSmithKline PLC
13 June 2014
 



 

Notification of Transactions of

Directors and Persons Discharging Managerial Responsibility

 

Award under the GlaxoSmithKline Deferred Investment Award programme

 

I give below details of changes in the interests of the under-mentioned Persons Discharging Managerial Responsibility ("PDMRs") in the Ordinary Shares of the Company ("Ordinary Shares") as a result of awards made under the GlaxoSmithKline Deferred Investment Award programme on 12 June, 2014.

 

Awards are made over notional Ordinary Shares with vesting phased over a specified period to provide long-term alignment with shareholders.  Vesting is subject to the individual not having served the Company notice or having been terminated by the Company for cause.  Notional dividends will accrue on the award during the vesting period through dividend reinvestment in additional notional shares.  On vesting, the award and accrued dividends will be paid in cash.  Executive Directors are not eligible to receive awards under the programme.  

 

For the following PDMRs, 50% of the award will vest on 23 September, 2016, 50% of the remaining balance of the award will vest on 23 September, 2017 and the remainder will then vest on 23 September, 2018.

 

PDMR

 

Number of notional Ordinary Shares subject to the award

Roger Connor

24,748.646

Abbas Hussain

30,935.808

David Redfern

24,748.646

Claire Thomas

24,748.646

Patrick Vallance

30,935.808

 

For the following PDMR, 50% of the award will vest on 23 September, 2017, 50% of the remaining balance of the award will vest on 23 September, 2018 and the remainder will then vest on 23 September, 2019.

 

PDMR

 

Number of notional Ordinary Shares subject to the award

Emma Walmsley

30,935.808

 

All of the above awards were made on 12 June, 2014. The awards were determined using an Ordinary Share price of £16.1625, the average of the high and low prices quoted on the London Stock Exchange on 12 June, 2014.

 

The Company and PDMRs were advised of these transactions on 13 June, 2014.

 

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

 

Victoria A Whyte

Company Secretary

 

13 June, 2014


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSXXLFFZQFBBBL

Companies

GSK (GSK)
UK 100

Latest directors dealings